Medicare may sound like an escape from the expensive world of U.S. health insurance, but it’s more complicated, and expensive, than many realize.
Inventiva stock sinks 20% after serious adverse event in NASH trial leads to enrollment pause
Inventiva has paused screening and entering new patients in its Phase III NASH study for lanifibranor after a possibly treatment-related adverse event. The company said
February 17, 2024